BrightRock Gold Corp (BRGC)

[langlui]

NFRM News April 6th

National Pharmaceuticals Lead Therapeutic Drug, GLB333 Application in Lupus
Wednesday April 6, 2011, 12:30 am EDT

MIAMI, FLORIDA--(Marketwire - 04/06/11) - National Pharmaceuticals Corp. (PINK SHEETS:NFRM - News) or the "Company" is pleased to announce that its partner, Globe Laboratories concluded that GLB333, the Company's Lead Therapeutic drug may have effect in the treatment of Lupus. Lupus complications are caused by over expression of certain cytokine (interleukins) according to several scientific reports. The drug GLB333 is an inhibitor of a cytokine that is involved in lupus. Globe Labs has indicated that the drug should be beneficial to treat lupus, due to its inhibitory action on cytokine or interleukin function. There are approximately 1,400,000 lupus patients in the United States according to the Scripps Magazine report (http://www.scripps.edu/philanthropy/lupus.html?origin=ggdislupus). To date there is no effective treatment availed for lupus sufferers. While the actual cause of the disease is not known, but the presence of cytokines or interleukins are well documented.

About lupus

Lupus, an autoimmune disease, happens when the immune system attacks its tissues, causing inflammation, swelling, pain, and damage. Lupus symptoms vary, and early lupus symptoms include fatigue, joint pain, fever, and a lupus rash, especially after being in the sun. Familiarize yourself with pictures of the lupus rash. Doctors diagnose lupus by symptoms and blood tests. Lupus is not contagious but has a hereditary component. For information, please visit the lupus Foundation of America (http://www.lupus.org/newsite/index.html).